GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc. (NYSE:MRK)’s immunotherapy Keytruda significantly reduces the risk of disease ...

Data from the phase III ASCENT-04/KEYNOTE-D19 showed Trodelvy plus Merck’s MRK blockbuster immuno-oncology drug Keytruda reduced the risk of disease progression or death by 35% compared with ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...